Skip to Content
Get key facts and figures about chronic dry eye

Gatifloxacin ophthalmic Pregnancy and Breastfeeding Warnings

Gatifloxacin ophthalmic is also known as: Zymar, Zymaxid

Gatifloxacin ophthalmic Pregnancy Warnings

Animal studies have failed to reveal evidence of teratogenicity after oral doses up to 50 mg/kg/day (about 1000-fold higher than the maximum recommended ophthalmic dose); oral doses at least 150 mg/kg/day showed decreased fetal weight, atrial enlargement, and skeletal/craniofacial malformations or delayed ossification in rats, while increased late postimplantation loss and neonatal/perinatal mortalities were observed at 200 mg/kg/day. There are no controlled data in human pregnancy. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus. US FDA pregnancy category: C

See references

Gatifloxacin ophthalmic Breastfeeding Warnings

Caution is recommended. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: -Maternal use of an ophthalmic or otic drop containing this drug poses negligible risk for a nursing infant. -Placing pressure over the tear duct by the corner of the eye for at least 1 minute then removing excess solution with an absorbent tissue substantially reduces the amount of drug that reaches the breast milk after using eye drops.

Traditionally, systemic fluoroquinolones have not been used in infants due to concern over toxic effects on their developing joints; however, some studies suggest risk is low. Absorption of the small amounts of fluoroquinolones in milk may be blocked by the calcium in milk; data insufficient to prove or disprove.

See references

References for pregnancy information

  1. "Product Information. Zymaxid (gatifloxacin ophthalmic)." A-S Medication Solutions, Chicago, IL.
  2. "Product Information. Zymar (gatifloxacin ophthalmic)." Allergan Inc, Irvine, CA.

References for breastfeeding information

  1. "Product Information. Zymaxid (gatifloxacin ophthalmic)." A-S Medication Solutions, Chicago, IL.
  2. "Product Information. Zymar (gatifloxacin ophthalmic)." Allergan Inc, Irvine, CA.
  3. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.